Document is current
Any future updates will be listed below
-
Authors
Schwartz, Gregory G. http://orcid.org/0000-0003-2954-0695
Nicholls, Stephen J.
Toth, Peter P.
Sweeney, Michael
Halliday, Christopher
Johansson, Jan O.
Wong, Norman C. W.
Kulikowski, Ewelina
Kalantar-Zadeh, Kamyar
Ginsberg, Henry N.
Ray, Kausik K.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02586155 at ClinicalTrials.govDocuments that mention this clinical trial
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
https://doi.org/10.1186/s12933-021-01311-9
-
Funding
Funding for this research was provided by:
Resverlogix Corporation
- License Information
-
More Information
Article History
Received: 6 March 2021
Accepted: 3 June 2021
First Online: 22 June 2021
Declarations
:
: The BETonMACE trial was approved by the responsible institutional review board at each participating site and each patient gave written, informed consent.
: All authors have reviewed and approved the content of this manuscript for publication. A portion of this work was presented in abstract form at the American Heart Association Scientific Sessions, November 2020.
: GGS has received research support to the University of Colorado from AstraZeneca, Resverlogix, Roche, Sanofi, and The Medicines Company. He is coinventor of pending US patent 62/806,313 (“Methods for Reducing Cardiovascular Risk”) assigned in full to the University of Colorado. SJN reports research grants from AstraZeneca, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and honoraria from AstraZeneca, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim. PPT reports speaker bureau compensation from Amarin, Amgen, Esperion, Merck, Novo-Nordisk; consultant compensation from Amarin, Amgen, bio89, Novartis, and Theravance. CH, JJ, EK, MS, and NCWW are employees of Resverlogix Corporation. KKZ has received honoraria from Abbott, Abbvie, ACI Clinical, Akebia, Alexion, Amgen, Ardelyx, Astra-Zeneca, Aveo, Braun, Cara Therapeutics, Chugai, Cytokinetics, Daiichi, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Kissei, Novartis, Pfizer, Regulus, Relypsa, Resverlogix, Dr. Schaer, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS-Pharma. HNG has received research support from AstraZeneca, Amgen, Pfizer and honoraria from Astrazeneca, Amgen, Pfizer, Merck, Kowa, Resverlogix, Regeneron, Sanofi. KKR reports honoraria from Resverlogix, Aegerion, Amgen, Pfizer, AstraZeneca, Cerenis, Akcea, The Medicines Company, Kowa, Novartis, Cipla, Eli Lilly, Algorithm, Takeda, Boehringer Ingelheim, Abbvie, Silence Therapeutics, Dr. Reddys, Bayer, Daiichi Sankyo, Esperion, Zuelling Pharma, Sanofi-Regeneron and Merck and grants from Sanofi-Regeneron and Merck.
